Limbic network co-localization predicts pharmacoresistance in dysplasia-related epilepsy
Annals of clinical and translational neurology
To evaluate the role of focal cortical dysplasia co-localization to cortical functional networks in the development of pharmacoresistance. One hundred thirty-six focal cortical dysplasia patients with 3.0 T or 1.5 T MRI were identified from clinical databases at Children's National Hospital. Clinico-radio-pathologic factors and network co-localization were determined. Using binomial logistic regression, limbic network co-localization (odds ratio 4.164 95% confidence interval 1.02-17.08, p = 0.048), and focal to bilateral tonic-clonic seizures (4.82, 1.30-18.03, p = 0.019) predicted pharmacoresistance. These findings provide clinicians with markers to identify patients with focal cortical dysplasia-related epilepsy at high risk of developing pharmacoresistance and should facilitate earlier epilepsy surgical evaluation.
Cohen, Nathan T.; Chang, Phat; Gholipour, Taha; Oluigbo, Chima; Vezina, L Gilbert; Xie, Hua; Zhang, Anqing; and Gaillard, William D., "Limbic network co-localization predicts pharmacoresistance in dysplasia-related epilepsy" (2023). GW Authored Works. Paper 3421.